Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 5, Pages 1133
Publisher
MDPI AG
Online
2022-02-23
DOI
10.3390/cancers14051133
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma
- (2021) Jin Hyun Kang et al. BMC CANCER
- 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
- (2021) A.L. Ho et al. ANNALS OF ONCOLOGY
- SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway
- (2021) M. Jung et al. ANNALS OF ONCOLOGY
- 560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations
- (2021) S. Crabb et al. ANNALS OF ONCOLOGY
- Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.
- (2021) Brindley Sonal Hapuarachi et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RET-mutated thyroid and lung cancer in the personalised medicine era
- (2021) Joanna Klubo-Gwiezdzinska Lancet Diabetes & Endocrinology
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands
- (2021) Jingjing Sun et al. Scientific Reports
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
- (2020) R. Kurzrock et al. ANNALS OF ONCOLOGY
- ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma
- (2020) Mattias K. Andersson et al. Oncogenesis
- Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase.
- (2020) Chundao Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network
- (2020) Alice Garrett et al. JOURNAL OF MEDICAL GENETICS
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers
- (2020) Glenn J. Hanna et al. ONCOLOGIST
- 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
- (2020) R. Ferrarotto et al. ANNALS OF ONCOLOGY
- Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
- (2020) M.J.M. Uijen et al. CANCER TREATMENT REVIEWS
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease
- (2020) Larissa Di Villeneuve et al. Frontiers in Oncology
- The biological function and clinical significance of SF3B1 mutations in cancer
- (2020) Zhixia Zhou et al. Biomarker Research
- Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class
- (2020) April Weaver et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
- (2020) Kevin Kalinsky et al. JAMA Oncology
- The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma
- (2020) Helen Adderley et al. ORAL ONCOLOGY
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
- (2019) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- UTX Mutations in Human Cancer
- (2019) Lu Wang et al. CANCER CELL
- Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
- (2019) Raghav Dogra et al. Anti-Cancer Agents in Medicinal Chemistry
- Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.
- (2019) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
- (2019) Alan Loh Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
- (2019) Dominic G. Rothwell et al. NATURE MEDICINE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
- (2019) Croce et al. Cancers
- Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool in diagnosing secretory carcinoma of salivary gland and detecting ETV 6‐ NTRK 3 fusion
- (2019) Bin Xu et al. HISTOPATHOLOGY
- Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
- (2019) Allen S. Ho et al. JOURNAL OF CLINICAL INVESTIGATION
- First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
- (2019) Paul V. Viscuse et al. Frontiers in Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma
- (2018) Matthew Dankner et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma
- (2018) Hideaki Takahashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
- (2017) Renata Ferrarotto et al. JOURNAL OF CLINICAL ONCOLOGY
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers
- (2017) Guido J.R. Zaman et al. MOLECULAR CANCER THERAPEUTICS
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Clinical relevance of androgen receptor alterations in prostate cancer
- (2017) Emma Jernberg et al. Endocrine Connections
- Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results
- (2017) Michael C. Heinrich et al. JAMA Oncology
- PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
- (2016) J.S. de Bono et al. ANNALS OF ONCOLOGY
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
- (2016) Magnus T. Dillon et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer
- (2015) Hideki Terai et al. ACS Chemical Biology
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Genomic landscape of salivary gland tumors
- (2015) Shumei Kato et al. Oncotarget
- Targeting the LKB1 Tumor Suppressor
- (2014) Rui-Xun Zhao et al. CURRENT DRUG TARGETS
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: A single institutional experience at a tertiary care center
- (2013) Anna Marcinow et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now